To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

GlaxoSmithKline20 enrolled

Overview

A study to investigate the effects GSK561679 on part of the body's system that controls the balance of many of the hormones (including cortisol).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Enrollment

Conditions

Depressive Disorder and Anxiety Disorders

Interventions

metyraponeDRUG

Metyrapone will be available as 250 mg dose capsule.

alprazolamDRUG

Alprazolam capsules will be available with dose strength of 0.25mg

placeboDRUG

GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion: * Healthy male subjects * non-smoker * normal ECG Exclusion: * shift workers * vegetarians * persons who travel distances * persons participating in a psychology or psychiatry course

Locations (1)

GSK Investigational Site

Cambridge, Cambridgeshire, United Kingdom

Outcomes

Primary Outcomes

Blood levels of ACTH: over 24 hours

Time frame: Over 24 hours

Secondary Outcomes

Blood levels of GSK561679, metyrapone, alprazolam, cortisol: over 24 hours Questionnaires: each visit Safety (ECG/vital signs/Adverse Events/ laboratory): over 24 hours

Time frame: Over 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.